Inflammation and thrombosis in essential thrombocythemia
Two other inflammatory biomarkers, belonging to the superfamily of Pentraxins (PTXs) have been found to play a role as markers of thrombosis and atherogenesis in general population.
The first is the short pentraxin C-reactive protein (CRP), principally produced in hepatocytes, following stimulation by cytokines, especially interleukin-6 (IL-6). The introduction of high sensitivity assays has permitted the routine measurement and based on epidemiological studies, highsensitivity CRP (hs-CRP) has been incorporated into risk assessment for cardiovascular disease. 8 The second is the long Pentraxin-3 (PTX3), an acute-phase reactant considered more closely related than CRP to cardiac injuries such as myocardial infarction. 9, 10 However, whether PTX3 plays a role in the pathogenesis of thrombosis is still unclear. PTX3 is mainly produced by dendritic cells, macrophages, activated leukocytes and endothelial cells, and not by the liver, in response to primary inflammatory stimuli such as interleukin-1, tumor necrosis factor but not IL-6.
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We tested the hypothesis that blood levels of hs-CRP and PTX3 can be correlated with thrombotic complications in patients with ET and PV and explored the relationship with JAK2V617F mutation. PTX3 plasma levels were measured by an in-house Sandwich ELISA as previously described. 9 Detection limit is 100 pg/ml and inter-assay variability is 8-10%. Multivariate models considered sex (male versus female), age at sampling (> 60 years versus < 60 years), disease at diagnosis (ET versus PV), presence of almost one CV risk factor (yes versus no), JAK2 V617F allele burden (<50%, >50% versus JAK2 wild type) and hystory of hydroxyurea treatment (yes versus no). Logistic unadjusted and sequentially adjusted multivariate models were performed to assess for effect modification.
DESIGN and METHODS

Patients
RESULTS AND DISCUSSION
Patient characteristics at presentation are shown in Table 1 and reflect well the mix of clinical features found in routine clinical practice of care of unselected ET and PV patients. As expected, there was a prevalence of females in ET and a slight preponderance of males in PV.
JAK2V617F mutation was present in 97% (n=69) and in 63% (n=108) of PV and ET respectively.
Sixty-eight major thrombotic events were registered before blood sampling. Thirty-eight episodes (56%) were documented at diagnosis and 30 (44%) during follow-up. Aspirin was prescribed in large majority of cases and chemotherapy (Hydroxyurea) was given in 59% and 65% of ET and PV, respectively.
Clinical and haematological variables associated with tertiles of hs-CRP and PTX3
concentrations are presented in Table 2 .
Hs-CRP: the comparison between the third versus the first hs-CRP tertile (hs-CRP >3
versus <1 mg/L) showed a significant correlation with age (p=0.001), with phenotype (PV versus ET) (p=0.006), with presence of at least one CV risk factor (p=0.012) and with JAK2V617F allele burden >50% (p=0.003). There was a significantly higher proportion of patients who needed chemotherapy when hs-CRP values were higher than 3 mg/L. The number of patients with major thrombosis progressively increased according to increments of hs-CRP values (p=0.01).
PTX3: PTX3 values (<2.5; 2.5-4.5 and >4.5 ng/mL) showed a significant correlation with JAK2V617F allele burden >50% (p=0.01) and differently from hs-CRP, thrombotic episodes and CV risk factors were less frequent in the third tertile as compared with the first (p=0.0085). Factors influencing thrombotic risk according to hs-CRP and PTX3 levels were tested in multivariate models (Table 3) were not significant (p-values ranged from 0.06 to 0.23). In multivariate analysis sequentially adjusted for sex, age and ET or PV, cardiovascular risk factors, JAK2 mutation and hydroxyurea treatment, the odd ratios remained significantly higher in patients with hs-CRP levels more than 3 mg/L.
Concerning PTX3, in unadjusted and progressively adjusted models, we found significant and independent association with thrombosis, but differently to hs-CRP, odd ratios estimates were significantly inferior to 1, indicating that higher the levels less frequent were the vascular events.
We tested the interaction between hs-CRP and PTX3 in relation to the number of thrombotic events in multivariate model (Table S1, To our knowledge, this is the first study examining hs-CRP and PTX3 blood values and their association with vascular events in ET and PV.
In the general population, hs-CRP blood levels <1, 1 to 3, and >3 mg/L denote lower, average, and higher relative risk for future vascular events. In our ET and PV series the great majority of patients (n=170, 70%) had hs-CRP values largely exceeding normal concentrations (> 1mg/L).
Likewise, PTX3 plasma levels were significantly higher than the median level of our healthy controls and normal population. 13 Thus far, there have been no large population studies to determine the epidemiological association of plasma PTX3 and thrombosis.
In this paper we have found that levels of these biomarkers in ET and PV patients were significantly associated with the number of major thrombotic events but the effects of this association were completely different for hs-CRP and PTX3. For hs-CRP, odd ratios were comprised between 2.61 and 2.27 in all categories, indicating that the highest levels doubled the risk of thrombosis. This novel finding in MPN is consistent with results of several prospective studies showing that hs-CRP levels in general population are strongly associated with myocardial infarction, stroke and venous thrombosis 14 so that this inflammatory marker is currently recommended to recognize individuals at high cardiovascular risk and to quantify the efficacy of interventions 15 . For PTX3, we found that the highest were the levels, the fewer were patients with cardiovascular risk factors and thrombotic events. The explanation of this hitherto unknown effect in humans may be offered by recent experimental observations showing that, in mouse models, PTX3 released from activated leukocytes has anti-thrombotic effects likely through a regulatory role of inflammation. 16 This protective action consists in an attenuation of neutrophil recruitment at sites of inflammation 17 through a PTX3 binding to P-selectin on activated endothelial cells and platelets. 18, 19 Blood values of hs-CRP and PTX3 were correlated with JAK2V617F allele burden (p=0.003)
suggesting that this production may be due to the effect of gene transcription in the case of PTX3 
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